Phosphorylation-driven Targeted Protein Degradation of Oncogenic β-catenin

This study demonstrates that recruiting Casein kinase I (CSNK1) family members to oncogenic β-catenin via induced-proximity strategies triggers kinase-dependent, proteasome-mediated degradation of β-catenin, thereby inhibiting the growth of colorectal cancer cells with Wnt pathway mutations.

The Gist

The Big Problem: The "Stuck" Light Switch

Imagine your body is a giant house. Inside this house, there is a light switch called Wnt signaling. This switch controls how fast your cells grow and divide. In a healthy house, you flip the switch on to grow when you need to, and flip it off when you're done.

However, in many types of colon cancer, this switch gets jammed in the "ON" position. The culprit is a protein called $\beta$-catenin (beta-catenin). Think of $\beta$-catenin as the "gas pedal" for cell growth.

Normally, the body has a "brake system" (called the destruction complex) that catches the gas pedal, puts a lock on it, and throws it in the trash (degradation) so the car doesn't speed out of control. But in cancer, the lock is broken. The gas pedal is stuck, the car speeds up, and a tumor forms.

For years, scientists tried to build a new "brake" to stop this, but every time they tried, it either didn't work or it broke other parts of the house (causing side effects).

The New Idea: The "Molecular Glue"

The scientists in this paper asked a different question: Instead of trying to fix the broken brake, can we just grab the gas pedal and throw it in the trash ourselves?

This is a strategy called Targeted Protein Degradation (TPD). Imagine you have a special "Molecular Glue" (a drug). One end of the glue sticks to the bad gas pedal ($\beta$-catenin), and the other end sticks to the body's natural garbage disposal unit (the Proteasome). Once they are glued together, the garbage disposal eats the gas pedal, and the car slows down.

The Experiment: The "Wanted" Poster

The researchers wanted to find the perfect "glue" partners. They didn't guess; they ran a massive search.

1. The Setup: They took cancer cells and put a tiny "Glow-in-the-Dark" tag on every single $\beta$-catenin molecule inside them. Now, they could see exactly how much "gas pedal" was in the cell.
2. The Library: They had a library of about 15,000 different proteins (like a library of 15,000 different tools).
3. The Test: They forced each of these 15,000 tools to get very close to the glowing $\beta$-catenin.
   • Analogy: Imagine a room full of 15,000 people. You tell each person, "Go stand right next to the glowing ball." You then watch to see if the glowing ball disappears.

The Surprise Discovery: The "Recruiter"

Most scientists expected to find "garbage collectors" (E3 ligases) that would naturally eat the protein. They did find some of those.

But the big surprise was finding a "Recruiter" named CSNK1.

Think of CSNK1 not as a garbage collector, but as a foreman or a painter.

• Normally, the garbage disposal only eats things that have a specific "trash tag" (a phosphorylation mark) on them.
• In cancer, the $\beta$-catenin is missing this tag, so the garbage disposal ignores it.
• When the researchers forced CSNK1 to get close to $\beta$-catenin, CSNK1 acted like a painter. It painted a new "trash tag" onto the gas pedal.
• Once the tag was painted on, the body's natural garbage disposal recognized it and ate the $\beta$-catenin.

Why is this cool? It means we don't need to invent a new way to destroy the protein; we just need to trick the body into thinking the protein wants to be destroyed by giving it a fresh "trash tag."

The Results: Stopping the Cancer Car

The scientists tested this new strategy in two ways:

1. Direct Glue: They used a molecular glue to force CSNK1 and $\beta$-catenin together. Result: The $\beta$-catenin vanished, and the cancer cells stopped growing.
2. Small Molecule Switch: They used a tiny chemical drug (like a remote control) to snap CSNK1 and $\beta$-catenin together only when needed. Result: The cancer cells died, and healthy cells were fine.

They also found that this trick works even on the "broken" gas pedals found in cancer patients (mutated versions of $\beta$-catenin). This is huge because most previous drugs failed on these specific broken versions.

The Bigger Picture

This paper suggests a new rule for making cancer drugs:

• Old Rule: Find a way to block the bad protein.
• New Rule: Find a way to recruit a helper (like a kinase) to tag the bad protein, so the body's own trash can do the work.

It's like realizing that instead of trying to manually lift a heavy rock (the protein) out of the way, you just need to call a crane (the kinase) to tag it, and then the crane can easily lift it away.

Summary

The scientists found a way to trick cancer cells into destroying their own "growth engine" ($\beta$-catenin). They did this by forcing a helper protein (CSNK1) to tag the engine with a "destroy me" sticker. Once tagged, the cell's natural cleanup crew ate the engine, stopping the cancer from growing. This opens the door to a new generation of drugs that could treat cancers that have been impossible to cure so far.

Technical Summary

1. Problem Statement

The Wnt/β-catenin signaling pathway is a critical driver of colorectal cancer (CRC), particularly in cases where mutations in the APC gene or CTNNB1 (β-catenin) itself lead to ligand-independent stabilization of β-catenin. Despite its therapeutic potential, inhibiting this pathway has failed to reach the clinic due to two main challenges:

• Systemic Toxicity: Global inhibition of Wnt signaling disrupts tissue homeostasis (e.g., in bone and intestine) because the pathway is essential for stem cell maintenance.
• "Undruggability": β-catenin functions primarily through protein-protein interactions (PPIs) rather than enzymatic active sites, making it difficult to target with traditional small-molecule inhibitors.
• Limitations of Current TPD: While Targeted Protein Degradation (TPD) via PROTACs and molecular glues offers a solution, current strategies rely heavily on a limited set of E3 ubiquitin ligases (e.g., VHL, CRBN) and often fail to degrade mutant proteins that lack specific degron motifs or are stabilized by destruction complex mutations.

2. Methodology

The authors employed an unbiased, genome-scale induced-proximity screening strategy to identify proteins that, when brought into close proximity with β-catenin, trigger its degradation.

• Cell Line Engineering: They generated DLD-1 colorectal cancer cells (which harbor APC mutations) with endogenous, dual-tagging of both CTNNB1 alleles. One allele was tagged with eGFP and the other with eBFP2 at the N-terminus. This allowed for the simultaneous monitoring of both alleles via flow cytometry (FACS) and ensured that degradation required the loss of both fluorophores.
• Screening Library: A near-proteome-wide library of ~14,821 human Open Reading Frames (ORFs) was fused to an anti-GFP nanobody (vhhGFP). This nanobody constitutively recruits the ORF product to the GFP-tagged β-catenin.
• Screening Approaches:
  1. Phenotypic Screen (FACS): Identified ORFs causing a loss of eGFP/eBFP2 fluorescence (indicating protein degradation).
  2. Fitness Screen (Dropout): Identified ORFs that reduced cell proliferation (since β-catenin is essential for CRC growth).
• Validation & Mechanism:
  • Inducible Systems: To move beyond constitutive nanobody binding, they utilized small-molecule dimerization systems (FKBP12F36V/FRB* with Rapalog A/C; FKBP12F36V/HaloTag with PhosTAC7) to induce proximity between β-catenin and candidate proteins.
  • Mechanistic Dissection: Used kinase-dead mutants, chemical inhibitors (MG132, TAK243, MLN-4924, Bafilomycin A), and CRISPR/Cas9 suppressor screens to determine the degradation pathway.
  • Mutant Analysis: Tested various oncogenic β-catenin mutants (S45, T41, S37, S33) to assess the versatility of the degradation mechanism.
  • Generalizability: Tested the concept on SNAI1, another phospho-dependent substrate.

3. Key Contributions

• Discovery of Kinase-Mediated Degradation: The study identifies members of the Casein Kinase I (CSNK1) family, specifically CSNK1D, as potent inducers of β-catenin degradation, a mechanism distinct from traditional E3 ligase recruitment.
• Neo-Degron Formation: The authors propose a novel TPD mechanism where the forced recruitment of a kinase to a substrate creates a neo-phospho-degron. This restores the degradation signal in contexts where the native destruction complex is defective (e.g., APC mutations).
• Bypassing the Destruction Complex: The study demonstrates that CSNK1D-mediated degradation bypasses the need for GSK3α/β and AXIN, which are often mutated or dysfunctional in cancer, relying instead on the SCF^β-TrCP (FBXW11) E3 ligase complex.
• Broad Applicability: The strategy successfully degrades oncogenic β-catenin mutants (S45del, T41A) that typically escape degradation, and extends to other substrates like SNAI1.

4. Key Results

• Screening Hits: The unbiased screen identified E3 ligases (validating the approach) but highlighted CSNK1D and SIAH2 as top hits. CSNK1D induced robust degradation of both eGFP- and eBFP2-tagged β-catenin, surpassing the positive control FBXL15.
• Mechanism of Action:
  • Kinase-Dependent: Kinase-dead mutants of CSNK1D (K38R, E247K/L252P) failed to degrade β-catenin, confirming that kinase activity is required.
  • UPS-Dependent: Degradation was blocked by proteasome inhibitors (MG132) and E1 inhibitors (TAK243), but not lysosomal inhibitors. It required the SCF complex component FBXW11 (β-TrCP2).
  • Phosphorylation: The degradation relies on the formation of a phospho-degron. While CSNK1D phosphorylates S45 (priming), the subsequent phosphorylation of T41, S37, and S33 (likely by endogenous kinases or the recruited kinase complex) creates the binding site for β-TrCP.
• Small Molecule Induction: Using the Rapalog A/C Heterodimerizer to recruit CSNK1D-FKBP12F36V to FRB*-tagged β-catenin resulted in rapid degradation, downregulation of Wnt target genes (e.g., AXIN2, ASCL2), and significant inhibition of CRC cell proliferation over 14 days.
• Mutant Resistance: Unlike traditional degradation mechanisms that fail on S45/T41 mutants, CSNK1D-induced proximity successfully degraded S45del and T41A mutants. This is crucial as these are the most common oncogenic mutations in CRC.
• CRISPR Suppressor Screen: A genome-wide screen confirmed that FBXW11 is essential for this degradation, while GSK3A/B and AXIN1/2 were dispensable, proving the pathway bypasses the canonical destruction complex.
• Generalizability: Forced recruitment of CSNK1D also degraded SNAI1, a transcriptional regulator dependent on phospho-degrons, suggesting this strategy can be applied to other "undruggable" phospho-regulated proteins.

5. Significance

• New Paradigm for TPD: This paper introduces a "kinase-recruitment" strategy for TPD. Instead of linking a target directly to an E3 ligase, it links a target to a kinase to create a degron. This expands the chemical toolbox for targeting proteins that lack intrinsic degrons or are stabilized by disease mutations.
• Therapeutic Potential for CRC: By bypassing the defective destruction complex and targeting the most common oncogenic β-catenin mutations (S45/T41), this approach offers a viable path to treating Wnt-driven cancers that have been resistant to current therapies.
• Overcoming "Undruggability": It provides a solution for targeting protein-protein interaction hubs (like β-catenin) by converting them into substrates for the ubiquitin-proteasome system through phosphorylation.
• Future Directions: The authors suggest that developing bifunctional small molecules (PROTACs) that recruit CSNK1D to β-catenin (or other phospho-dependent targets) could lead to the first clinically effective Wnt inhibitors. While direct binders for β-catenin are currently limited, the "catch and release" mechanism using kinase inhibitors or cysteine-based chemistry is proposed as a feasible route.

In summary, the study demonstrates that induced proximity to CSNK1D restores the phospho-degron on oncogenic β-catenin, enabling its degradation by the endogenous SCF^β-TrCP complex and effectively inhibiting colorectal cancer growth, even in the presence of common resistance mutations.